SCHEMBL257419

SCHEMBL257419

Cc1ccc(-c2cnn3c(-c4ccc(F)cc4)cc(N4CCC[C@H]4CO)nc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT1 P42224 2/20 0.49
FPR2 P25090 1/20 0.45
SCN9A Q15858 1/20 0.45
NTRK1 P04629 3/20 0.44
BCL6 P41182 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
EGLN2 Q96KS0 2/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
TACR1 P25103 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15021303 1.00 STAT1 (0.49) STAT1FPR2SCN9ANTRK1BCL6
SCHEMBL15042218 0.85 BCL6 (0.54) STAT1BCL6NPC1RAB9AMAPT
SCHEMBL15020613 0.84 FPR2 (0.45) FPR2SCN9ABCL6MAPTKMT2A
SCHEMBL257208 0.84 FPR2 (0.45) FPR2SCN9ABCL6MAPTKMT2A
SCHEMBL15020690 0.82 ALDH1A1 (0.47) FPR2SCN9ABCL6MAPTSMN1; SMN2
SCHEMBL10072361 0.82 ALDH1A1 (0.47) FPR2SCN9ABCL6MAPTSMN1; SMN2
SCHEMBL15020820 0.81 FPR2 (0.42) FPR2SCN9ANTRK1BCL6MAPT
SCHEMBL256991 0.81 FPR2 (0.42) FPR2SCN9ANTRK1BCL6MAPT
SCHEMBL10071863 0.80 FPR2 (0.48) FPR2SCN9ANTRK1BCL6MAPT
SCHEMBL15020745 0.80 FPR2 (0.48) FPR2SCN9ANTRK1BCL6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 STAT1 2921/4885FPR2 2908/4885SCN9A 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.